Previous research has shown that treatment with SLV338, a neutral endopeptidase (NEP)/ECE inhibitor, diminished renal tissue damage (glomerulosclerosis, interstitial fibrosis and renal arterial remodeling) but did not significantly affect blood pressure [16]. Here, MME is linked to glomerulosclerosis.